Brilliant Therapeutics Private Limited
About Brilliant Therapeutics Private Limited
Data last updated:
Brilliant Therapeutics Private Limited is a private limited company based in Hyderabad, Telangana, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 03 November 2016 and has been in existence for over 10 years.
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U33112TG2016PTC112782. Its GSTIN is 36AAGCB9443D1ZP (Telangana).
The company has an authorised share capital of ₹5 Cr and a paid-up capital of ₹1 Lakh. It is led by directors Darla Prasad and Puvula Kanaka Rao.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Fifth Floor T.G.V. Mansion 6 – 2 – 1012 Rajbhavan Road Khairatabad, Hyderabad, Telangana, India – 500004.
As per the financials filed for FY 2025, the company reported a revenue of ₹1.44 Cr, a growth of 121% compared to the previous year. For the same year it recorded a net profit of ₹15.36 Lakh (net margin 10.6%) and EBITDA of ₹30.46 Lakh (EBITDA margin 21.1%). Revenue has grown at a compounded annual rate (CAGR) of 59% over three years and 42% over five years.
The current compliance status is marked as compliant by the Registrar of Companies.
Company details
Contact details
Brilliant Therapeutics Private Limited's registered office is in Hyderabad, Telangana. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered AddressFifth Floor T.G.V. Mansion 6 – 2 – 1012 Rajbhavan Road Khairatabad, Hyderabad, Telangana, India – 500004
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Brilliant Therapeutics Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Brilliant Therapeutics is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Brilliant Therapeutics Private Limited, buy the company report.
Financials of Brilliant Therapeutics Private Limited
FY 2025 filings availableBrilliant Therapeutics Private Limited reported revenue of ₹1.44 Cr (up 121% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 42% over five years, including 121% growth in the latest year. EBITDA rose 14% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹30.46 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹15.36 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 21.1% | ||||
| Net Profit Margin | 10.6% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Brilliant Therapeutics Private Limited, buy the company report.
Board of directors of Brilliant Therapeutics Private Limited
Brilliant Therapeutics has 2 current directors and 4 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Darla Prasad Also directs: Nectar Laboratories Private Limited | Director | 05 Oct 2019 | 7 Years 1 Months | Current |
| Puvula Kanaka Rao | Director | 30 Mar 2017 | 9 Years 7 Months | Current |
Auditor
Brilliant Therapeutics Private Limited is audited by KATRAPALLI & CO for the financial year 2017.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| KATRAPALLI & CO | FY 2017 | ACVPK4087E |
Shareholding
The shareholding of Brilliant Therapeutics Private Limited is on record for FY 2017, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2017 |
|---|---|
| Promoters | |
| Domestic institutional investors (DII) | |
| Foreign institutional investors (FII) | |
| Public | |
| Others |
To see the full shareholding pattern of Brilliant Therapeutics Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Brilliant Therapeutics Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Brilliant Therapeutics Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Brilliant Therapeutics has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 36AAGCB9443D1ZP | Telangana | Active | 30 Dec 2017 |
To see the full GST registrations and return filing status of Brilliant Therapeutics Private Limited, buy the company report.
Recent activity
Brilliant Therapeutics Private Limited has 6 board changes on record since 2017: 2 appointments and 4 cessations. The latest: Chandra Sekhar Korrapati ceased to be Director on 05 Oct 2019.
Frequently asked questions
Brilliant Therapeutics is an active private limited company based in Hyderabad, Telangana, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 03 November 2016 (10+ years old) and is registered under CIN U33112TG2016PTC112782.
Brilliant Therapeutics has 2 current directors:
- Darla Prasad - Director
- Puvula Kanaka Rao - Director
The latest financial statements of Brilliant Therapeutics on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2017 are in the company report.
The GSTIN of Brilliant Therapeutics is 36AAGCB9443D1ZP, registered in Telangana.
The CIN (Corporate Identification Number) of Brilliant Therapeutics is U33112TG2016PTC112782. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Brilliant Therapeutics was incorporated on 03 November 2016, making it 10+ years old. It is registered with the Registrar of Companies, Hyderabad.
Chandra Sekhar Korrapati ceased to be Director on 05 Oct 2019. Darla Prasad was appointed as Director on 05 Oct 2019. Ramaswamy Natesaiyer ceased to be Director on 27 Oct 2018. Brilliant Therapeutics has 6 board changes on record in total.
The registered office of Brilliant Therapeutics is at Fifth Floor T.G.V. Mansion 6 – 2 – 1012 Rajbhavan Road Khairatabad, Hyderabad, Telangana, India – 500004.
Brilliant Therapeutics operates in the pharma industry, in the drug formulation and development segment.
The compliance status of Brilliant Therapeutics is compliant as of 06 September 2026. The company is actively filing with the Registrar of Companies.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
